Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyHedy L. Kindler, Eric Van Cutsem, Richard Létourneau et al.|The Lancet Oncology|2011Cited by 396
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced CancersPatricia LoRusso, Alejandro D. Ricart, Smitha Krishnamurthi et al.|Clinical Cancer Research|2010Cited by 250